PointState Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

PointState Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-300,000	Closed	-$42.2M	–	103
2015 Q4	$42.2M	Buy	300,000 +243,600	+432%	+$33.8M	1.07%	20
2015 Q3	$7.49M	Sell	56,400 -571,500	-91%	-$98.4M	0.21%	55
2015 Q2	$111M	Buy	627,900 +426,300	+211%	+$76.6M	1.29%	21
2015 Q1	$34.8M	Buy	201,600 +121,600	+152%	+$20.9M	0.47%	51
2014 Q4	$13.1M	Buy	80,000 +5,000	+7%	+$830K	0.22%	75
2014 Q3	$12M	Sell	75,000 -325,000	-81%	-$50M	0.22%	60
2014 Q2	$58.8M	Buy	400,000 +275,000	+220%	+$38.1M	0.74%	29
2014 Q1	$17.3M	Buy	+125,000	New	+$18.8M	0.28%	58
2013 Q3	–	Sell	-275,000	Closed	-$18.9M	–	148
2013 Q2	$18.9M	Buy	+275,000	New	+$16.8M	0.33%	65

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PointState Capital's JAZZ Position: Q1 2016 in Review

PointState Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2016, closing a stake of 300,000 shares — an estimated $42.2M sold.

PointState Capital first reported a position in JAZZ in Q2 2013 and held it in 9 quarters. The position peaked at $111M in Q2 2015. 339 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

PointState Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
PointState Capital sold 300,000 Jazz Pharmaceuticals shares in Q1 2016, an estimated $42.2M.
PointState Capital first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 9 quarters.
PointState Capital's Jazz Pharmaceuticals position peaked at $111M in Q2 2015.
339 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on PointState Capital's 13F filing for Q1 2016, filed 16 May 2016.